Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Biofrontera (Nasdaq: BFRI) will report results for the three and nine months ended September 30, 2025 after U.S. market close on Wednesday, November 12, 2025. The company will host a conference call and webcast to discuss the results, provide a business update and answer questions on Thursday, November 13, 2025 at 10:00am ET.
Conference call numbers and an investor webcast will be available for live participation. Biofrontera commercializes the drug-device combination Ameluz with the RhodoLED lamp series for photodynamic therapy (PDT) and is conducting clinical trials to expand indications to non-melanoma skin cancers and moderate to severe acne.
Biofrontera (Nasdaq: BFRI) riferirà i risultati per i tre e i nove mesi terminati 30 settembre 2025 dopo la chiusura del mercato statunitense mercoledì 12 novembre 2025. L'azienda terrà una conference call e una webcast per discutere i risultati, fornire un aggiornamento sull'attività e rispondere alle domande il giovedì 13 novembre 2025 alle 10:00 ET.
I numeri della conference call e una webcast per investitori saranno disponibili per partecipare in diretta. Biofrontera commercializza la combinazione farmaco-dispositivo Ameluz con la serie di lampade RhodoLED per la fototerapia fotodinamica (PDT) e sta conducendo studi clinici per espandere le indicazioni a tumori cutanei non melanoma e all'acne da moderata a grave.
Biofrontera (Nasdaq: BFRI) informará los resultados de los tres y nueve meses finalizados el 30 de septiembre de 2025 tras el cierre del mercado de EE. UU. el miércoles 12 de noviembre de 2025. La empresa organizará una conferencia telefónica y una webcast para discutir los resultados, proporcionar una actualización comercial y responder preguntas el jueves 13 de noviembre de 2025 a las 10:00 a. m. ET.
Los números de la conferencia y una webcast para inversionistas estarán disponibles para participar en vivo. Biofrontera comercializa la combinación fármaco-dispositivo Ameluz con la lámpara RhodoLED para la fototerapia (PDT) y está llevando a cabo ensayos clínicos para ampliar las indicaciones a cánceres de piel no melanoma y a acné de moderado a severo.
Biofrontera (나스닥: BFRI)는 2025년 9월 30일에 종료된 3개월 및 9개월의 실적을 미국 시장 마감 후인 2025년 11월 12일 수요일에 발표합니다. 회사는 결과를 논의하고, 사업 업데이트를 제공하며 질의응답을 위한 컨퍼런스 콜과 웹캐스트를 2025년 11월 13일 목요일 오전 10:00 동부시간에 주최할 예정입니다.
컨퍼런스 콜 번호 및 투자자 웹캐스트가 라이브 참여를 위해 제공됩니다. Biofrontera는 PDT(광역동요법)를 위한 Ameluz와 RhodoLED 램프 시리즈의 약물-장치 결합을 상용화하며, 비멜노마 피부암과 중등도에서 심한 여드름에 대한 적응증 확장을 위한 임상시험을 진행 중입니다.
Biofrontera (Nasdaq : BFRI) publiera les résultats pour les trois et neuf mois se terminant le 30 septembre 2025 après la clôture du marché américain le mercredi 12 novembre 2025. L’entreprise organisera une conférence téléphonique et une webcast pour discuter des résultats, fournir une mise à jour commerciale et répondre aux questions le jeudi 13 novembre 2025 à 10 h HE.
Les numéros de conférence téléphonique et une webcast investisseurs seront disponibles pour une participation en direct. Biofrontera commercialise la combinaison médicament-dispositif Ameluz avec la lampe RhodoLED pour la photodynamique (PDT) et mène des essais cliniques pour étendre les indications aux cancers de la peau non mélanocytaires et à l’acné de modérée à sévère.
Biofrontera (Nasdaq: BFRI) wird die Ergebnisse für die drei und neun Monate beendet am 30. September 2025 nach Handelsschluss in den USA am Mittwoch, dem 12. November 2025 bekannt geben. Das Unternehmen wird eine Conference Call und einen Webcast veranstalten, um die Ergebnisse zu besprechen, ein Unternehmensupdate zu geben und Fragen zu beantworten am Donnerstag, dem 13. November 2025 um 10:00 Uhr ET.
Teilnahme per Live-Anruf und Investor-Webcast wird zur Verfügung stehen. Biofrontera vermarktet die Drogen-Device-Kombination Ameluz mit der RhodoLED-Lampenserie für die photodynamische Therapie (PDT) und führt klinische Studien durch, um Indikationen auf Hautkrebs nicht-melanozytär und mittels bis schwerer Akne zu erweitern.
Biofrontera (ناسداك: BFRI) ستعلن عن النتائج لثلاثة أشهر وتسعة أشهر المنتهية في 30 سبتمبر 2025 بعد إغلاق السوق الأمريكية يوم الأربعاء 12 نوفمبر 2025. ستعقد الشركة مكالمة مؤتمرات وبثًا مباشرًا على الويب لمناقشة النتائج، وتقديم تحديث أعمال والإجابة على الأسئلة في الخميس 13 نوفمبر 2025 في الساعة 10:00 صباحًا بتوقيت شرق الولايات المتحدة.
سيكون هناك أرقام لمكالمة المؤتمر وبث مباشر للمستثمرين متاحة للمشاركة المباشرة. Biofrontera تروّج لمزيج الدواء-الجهاز Ameluz مع سلسلة المصابيح RhodoLED للعلاج بالضوء الديناميكي الحيوي (PDT) وتقوم بإجراء تجارب سريرية لتوسيع المؤشرات إلى سرطان الجلد غير الميلانيني وحب الشباب من المعتدل إلى الشديد.
- None.
- None.
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, November 13, 2025 |
| Time: | 10:00am ET |
| Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Webcast - Biofrontera Inc. 3Q25 Results Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will Biofrontera (BFRI) release third quarter 2025 financial results?
What time is the Biofrontera (BFRI) Q3 2025 conference call?
How can investors access the Biofrontera (BFRI) Q3 2025 webcast and call?
What will Biofrontera (BFRI) discuss on the November 13, 2025 call?
What products does Biofrontera (BFRI) commercialize that relate to the update?
